Neurocrine Biosciences (NBIX) Deferred Taxes (2010 - 2026)
Neurocrine Biosciences (NBIX) posted Deferred Taxes of -$61.1 million for Q1 2026, down 226.76% on a QoQ basis from $48.2 million in Q4 2025, and down 345.99% year-over-year from $24.8 million in Q1 2025.
Neurocrine Biosciences (NBIX) Deferred Taxes (2010 - 2026) Analysis & Trends
Neurocrine Biosciences' Deferred Taxes history runs 16 years deep, the most recent figure standing at -$61.1 million for Q1 2026.
- Quarterly Deferred Taxes fell 345.99% year-over-year to -$61.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $118.0 million (up 197.36% YoY) and the FY2025 annual result came in at $165.4 million, up 234.36% from the prior year.
- Deferred Taxes was -$61.1 million for Q1 2026 at Neurocrine Biosciences, down from $48.2 million in the prior quarter.
- Across five years, Deferred Taxes topped out at $168.3 million in Q3 2025 and bottomed at -$61.1 million in Q1 2026.
- A 5-year average of -$3.3 million and a median of -$13.7 million in 2025 frame the typical range for Deferred Taxes.
- Annual changes were most pronounced in 2023 — Deferred Taxes slumped 10433.33% — and 2025, when it soared 582.23%.
- Neurocrine Biosciences' Deferred Taxes stood at $13.5 million in 2022, then jumped by 52.59% to $20.6 million in 2023, then slumped by 251.94% to -$31.3 million in 2024, then surged by 253.99% to $48.2 million in 2025, then sank by 226.76% to -$61.1 million in 2026.
- Business Quant data shows NBIX's Deferred Taxes at -$61.1 million in Q1 2026, $48.2 million in Q4 2025, and $168.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -22.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 34.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 25.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -69.70 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -61.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 2.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -61.10 Mn |
| Dec 31, 2025 | 48.20 Mn |
| Sep 30, 2025 | 168.30 Mn |
| Jun 30, 2025 | -37.40 Mn |
| Mar 31, 2025 | -13.70 Mn |
| Dec 31, 2024 | -31.30 Mn |
| Sep 30, 2024 | -34.90 Mn |
| Jun 30, 2024 | -41.30 Mn |
| Mar 31, 2024 | -15.60 Mn |
| Dec 31, 2023 | 20.60 Mn |
| Sep 30, 2023 | -4.20 Mn |
| Jun 30, 2023 | -41.50 Mn |
| Mar 31, 2023 | -31.60 Mn |
| Dec 31, 2022 | 13.50 Mn |
| Sep 30, 2022 | 9.00 Mn |
| Jun 30, 2022 | -3.10 Mn |
| Mar 31, 2022 | -300,000.00 |
| Dec 31, 2021 | -4.70 Mn |
| Sep 30, 2021 | 5.70 Mn |
| Jun 30, 2021 | 9.50 Mn |